Table 2

Pulmonary hemodynamics at baseline and targeted pulmonary arterial hypertension (PAH) therapy in twenty-two patients with PAH undergoing oscillatory whole-body vibration (WBV) in the “WBV only” and “Control-WBV” (initial control, subsequent WBV) groups

WBV only (n=11)Control-WBV (n=11)All (n=22)
 PAP systolic (mm Hg)58.5±8.464.5±5.561.5±4.9
 PAP diastolic (mm Hg)20.7±2.625.6±3.123.2±2.1
 PAP mean (mm Hg)35.5±4.241.9±3.638.7±2.8
 PAWP (mm Hg)11.1±1.19.3±1.110.2±0.8
 TPG (mm Hg)24.7±4.633.2±3.328.9±2.9
 DPG (mm Hg)9.6±3.016.4±2.813.0±2.1
 Cardiac output (L/min)4.3±0.24.6±0.34.5±0.2
 Cardiac index (L/min/m2)2.4±0.12.5±0.12.4±0.1
 PVR (WU)5.8±0.97.6±1.16.7±0.7
Targeted PAH therapy
 PDE5i monotherapy (n,%)6 (55)1 (9)7 (32)
 ERA+PDE5i (n, %)2 (18)5 (46)7 (32)
 ERA+sGC-S (n,%)1 (9)2 (18)3 (14)
 ERA+PDE5i+PCA (n,%)1 (9)2 (18)3 (14)
 PDE5i+TKI (n, %)01 (9)1 (4)
 ERA+PDE5i+TKI (n, %)1 (9)01 (4)
  • Values represent numbers of patients (n, %) or mean values±SEM.

  • DPG, diastolic pressure gradient (=PAPdiast – PAWP); ERA, Endothelin receptor antagonist; PAP, Pulmonary artery pressure; PAWP, Pulmonary arterial wedge pressure; PCA, Prostanoid; PDE5i, Phosphodiesterase type 5 inhibitor; PVR, Pulmonary vascular resistance (=TPG/CO); SEM, standard error of the mean; sGC-S, soluble guanylate cyclase stimulator; TKI, Tyrosine kinase inhibitor; TPG, transpulmonary pressure gradient (=PAPmean—PAWP).